| Clinical data | |
|---|---|
| Other names | 3,4-Methylenedioxy-β-hydroxyphenethylamine; β-Hydroxy-3,4-methylenedioxyphenethylamine; β-Hydroxy-MDPEA; Methylenedioxyethanolamine; MDE |
| Routes of administration | Oral |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | Unknown |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C9H11NO3 |
| Molar mass | 181.191 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
BOHH, also known as 3,4-methylenedioxy-β-hydroxyphenethylamine or as β-hydroxy-MDPEA, is a chemical compound of the phenethylamine, MDxx, and BOx families related to 3,4-methylenedioxyphenethylamine (MDPEA). It is the β-hydroxy derivative of MDPEA and the β-O-desmethyl analogue of BOH (β-methoxy-MDPEA). The drug is also the 3,4-methylenedioxy analogue of the neurotransmitter norepinephrine.
According to Alexander Shulgin in his book Phenethylamines I Have Known and Loved (PiHKAL) and other publications, BOHH is inactive at doses of up to 100 mg orally. On the other hand, Michael Valentine Smith claimed in his book Psychedelic Chemistry that BOHH "is said to be a very fine trip", with no other information provided.
BOHH was first described in the scientific literature by at least 1981. Subsequently, it was described in greater detail by Shulgin in PiHKAL in 1991.
The analogous derivative of BOH is 3,4-methylenedioxyphenyl-β-ethanolamine (BOHH). In the early literature it is occasionally referred to by the name MDE but this code has now been exclusively assigned to the N-ethyl homologue of MDMA. It is inactive at an oral dosage of 100mg. The corresponding dimethoxy compound (3,4-dimethoxyphenyl-ẞ-ethanolamine, DME) has been studied at doses of up to 115mg and is without psychoactivity.
Beta-hydroxy-3,4-methylenedioxyphenylethyl amine is said to be a very fine trip.